GlobeNewswire

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
19/12/2025
SAN CARLOS, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
19/12/2025
SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) announced today that it will be rescheduling its upcoming special meeting of [...]
Major shareholder announcement
19/12/2025
Pursuant to Section 30 of the Danish Capital Markets Act, ALK (ALKB:DC / OMX: ALK B) hereby announces that Arbejdsmarkedets Tillægspension (“ATP”) (The Danish Supplementary Labour Market Pension) has informed ALK that [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/12/2025
NOVATO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/12/2025
WALTHAM, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Lifeward Appoints Bob Marshall as Chairman of the Board
19/12/2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd ., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the [...]
Nyxoah Announces Issuance of First Tranche of Convertible Bonds
19/12/2025
Nyxoah Announces Issuance of First Tranche of Convertible Bonds Mont-Saint-Guibert, Belgium – December 19, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“ Nyxoah ” or the “ Company ”), a [...]
Nyxoah Annonce L’Émission de la Première Tranche des Obligations Convertibles
19/12/2025
Nyxoah Annonce L’Émission de la Première Tranche des Obligations Convertibles Mont-Saint-Guibert, Belgique – 19 décembre 2025, 10:05p.m. CET / 4:05 p.m. ET – Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) (« Nyxoah » ou la [...]
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
19/12/2025
Reducing inflammation helps create a regenerative environment in the Central Nervous System TORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ [...]
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
19/12/2025
WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
19/12/2025
Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, [...]
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
19/12/2025
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First FDA-Approved Medicine Company [...]
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
19/12/2025
Not intended for UK audiences Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function. 1 , 2 Affecting up to 100,000 people in the U.S. and [...]
Third-Party Recognition Underscores Genesis Healthcare’s Ongoing Commitment to Excellence in Skilled Nursing Care
19/12/2025
KENNETT SQUARE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genesis Healthcare, Inc. (Genesis) today announced that multiple of its affiliated skilled nursing facilities have earned national recognition from U.S. News & [...]
Novartis and US government reach agreement on lowering drug prices in the US
19/12/2025
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricing Additional Novartis medicines will be made available through direct-to-patient platforms in 2026 Company remains committed [...]
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
19/12/2025
Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump’s four requests, establishing a framework for lower prices for patients in the [...]
Communiqué de presse : Sanofi conclut un accord avec le gouvernement américain pour réduire le coût des médicaments et renforcer l’innovation
19/12/2025
Sanofi conclut un accord avec le gouvernement américain pour réduire le coût des médicaments et renforcer l’innovation L’accord répond aux quatre demandes du président Trump, établit un cadre pour que les patients [...]
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
19/12/2025
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi [...]
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
19/12/2025
NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum